

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/695,499
				Filing Date	October 28, 2003
				First Named Inventor	Vincenzo SCARLATO
				Art Unit	1645
				Examiner Name	J. Graser
Sheet	1	of	3	Attorney Docket Number	223002099101

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1.	Second Declaration of Garnett H. Helsoe, D.Sc. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit No. 1039. 21 pages.	
	2.	Fredriksen et al. (December 1991). "Production, Characterization And Control Of MenB-Vaccine <<Folkehelsa>>: An Outer Membrane Vescicle Vaccine Against Group B Meningococcal Disease," NIHP Annals 14(2): 67-80. (Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit No. 1040.)	
	3.	UniProtKB Entry: Q9JR18_NEIME. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit No. 1041. 3 pages.	
	4.	Koeberling et al. (2007). "Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870," Vaccine 25:1912-1920. (Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit No. 1042)	
	5.	Achtman et al. (August 1988). "Purification And Characterization Of Eight Class 5 Outer Membrane Protein Variants From A Clone Of Neisseria Meningitidis Serogroup A," J. Exp. Med. 168: 507-525. (Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 1044.)	
	6.	U.S.A. Patent Application No. 10/896,778. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 1045. 7 pages.	
	7.	van Ulsen (2001). "In vivo expression of Neisseria meningitidis proteins homologous to the Haemophilus influenzae Hap and Hia autotransporters," FEMS Immunology and Medical Microbiology 32:53-64. (Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 1046.)	
	8.	Second Declaration of Diana Lee. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 1047. 5 pages.	
	9.	Sequence Data. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 1048. 6 pages.	
	10.	Sequence Alignment. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit	

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/695,499
				Filing Date	October 28, 2003
				First Named Inventor	Vincenzo SCARLATO
				Art Unit	1645
				Examiner Name	J. Graser
Sheet	2	of	3	Attorney Docket Number	223002099101

		1049. 1 pages.	
	11.	Sequence Alignment. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 1050. 1 pages.	
	12.	Ruelle Priority Statement. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 1052. 7 pages.	
	13.	Deposition Upon Oral Examination Of Ralph C. Judd. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 1053. 37 pages.	
	14.	Deposition of Ralph C. Judd, PhD. January 16, 2008. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 1054. 10 pages.	
	15.	United Kingdom Patent Application No. 9810276.7. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2001. 67 pages.	
	16.	PCT Patent Application No. PCT/EP99/03255. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2002.. 79 pages.	
	17.	Declaration of Ralph C. Judd, Ph.D. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2004. 19 pages.	
	18.	Curriculum Vitae of Ralph C. Judd. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2005. 16 pages.	
	19.	Comparison of SEQ ID NO: 2 in United Kingdom Patent Application No. 9810276 and SEQ ID NO: 2 in U.S. Patent No. 6,780,419. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2006. 3 pages.	
	20.	Rosenqvist et al. (Dec. 1995). "Human Antibody Responses to Meningococcal Outer Membrane Antigens after Three Doses of the Norwegian Group B Meningococcal Vaccine," Infection and Immunity 63(12):4642-4652. (Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2007.)	
	21.	GenBank Submission with Accession No. AAF42523. Ruelle v. Scarlato: Interference No. 105,551. 2 pages. (Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2008.)	
	22.	U.S. Patent Application No. 11/212,443. Ruelle v. Scarlato: Interference No. 105,551. 139 pages. (Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2009 1(a).)	
	23.	Declaration and Sequence Data for U.S. Patent Application No. 11/212,443. Ruelle v. Scarlato: Interference No. 105,551. 136 pages. (Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2009 1(b).)	
	24.	Sequence Data for U.S. Patent Application No. 11/212,443. Ruelle v. Scarlato: Interference No. 105,551. 146 pages. (Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2009 1(c).)	
	25.	Sequence Data for U.S. Patent Application No. 11/212,443. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2009 Part 2. 188 pages.	
	26.	The American Heritage Dictionary. Second College Edition (1982). Library of Congress Cataloging in Publication Data. Page 680. (Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2010.)	
	27.	van der Ley et al. (Aug. 1992). "Construction of a Multivalent Meningococcal Vaccine Strain Based on the Class 1 Outer Membrane Protein," Infection and Immunity 60(8): 3156-3161. (Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2011.)	
	28.	Scarlato Clean Copy Of Claims 18-32 of U.S. Patent 11/212,443. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2012.	
	29.	U.S. Patent Application No. 10/896,778. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2013. 70 pages.	
	30.	Supplemental Amendment Filed September 24, 2007 for U.S. Patent Application No. 10/896,778. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2014. 5 pages.	
	31.	Deposition of Garnett H. Kelsoe, D.Sc (January 25, 2008). Submitted in Ruelle v. Scarlato:	

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/695,499
				Filing Date	October 28, 2003
				First Named Inventor	Vincenzo SCARLATO
				Art Unit	1645
				Examiner Name	J. Graser
Sheet	3	of	3	Attorney Docket Number	223002099101

		Interference No. 105,551 as Exhibit 2016. 72 pages.	
	32.	Second Declaration of Ralph C. Judd, Ph.D. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2017. 20 pages.	
	33.	Rogozin et al. (2002). "Congruent evolution of different classes of non-coding DNA in prokaryotic genomes," Nucleic Acids Research, 30(19):4264-4271. (Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2020.)	
	34.	Zhou et al. (2005). "A fractal method to distinguish coding and non-coding sequences in a complete genome based on a number sequence representation," Journal of Theoretical Biology 232:559-567. (Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2021.)	
	35.	Parkhill et al. (March 2000). "Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491," Nature 404(30):2-6. (Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2022.)	
	36.	Jordens et al. (2005). "A novel porA-based real-time PCR for detection of meningococcal carriage," Journal of Medical Microbiology 54:463-466. (Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2023.)	
	37.	ORF Finder Results for SEQ ID NO: 4 of Scarlato Exhibit 1007. Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2024. 6 pages.	
	38.	Handbook of Meningococcal Disease: Infection Biology, Vaccination, Clinical Management. Forsch, M. and Maiden M.C.J. (eds), Wiley-VCH Verlag GmbH & Co. KGaA. Page 84. (Submitted in Ruelle v. Scarlato: Interference No. 105,551 as Exhibit 2025.)	
	39.	McCarvil et al. (1993). "Expression of meningococcal epitopes in LamB of Escherichia coli and the stimulation of serosubtype-specific antibody responses," Molecular Microbiology 10(1): 203-213.	
	40.	van der Ley et al. (Oct. 1993). "Use of Transformation To Construct Antigenic Hybrids of the Class 1 Outer Membrane Protein in Neisseria meningitidis," Infection and Immunity 31(10): 4217-4224.	
	41.	Ward et al. (1996). "Expression of Neisseria meningitidis class 1 porin as a fusion protein in Escherichia coli: the influence of liposomes and adjuvants on the production of a bactericidal immune response," Microbial Pathogenesis, 21:499-512.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.